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Mouse skin painting has long been used to
assess the dermal carcinogenic potential of
natural and synthetic materials (1-4).
Compounds derived from petroleum were
among the early materials tested by mouse
skin painting and were important in
demonstrating the carcinogenic potential
of compounds such as polycyclic aromatic
hydrocarbons (PAHs) of specific structure
and elucidating the structure-activity rela-
tions now recognized for these com-
pounds.
Early investigators (2,5) painted the
skin ofmice for long periods oftime until
or after the appearance oftumors. Modern
investigators using this technique apply
materials for periods approximating the
lifetime of the mouse, particularly since
promulgation of the FDA and EPA Good
Laboratory Practice Regulations (6,7). It
was learned that some materials could
cause tumors after a few (or single) applica-
tions but only after subsequent longer-
term administration of substances that
were not necessarily active in the absence
of the initial material (8,9). The active
materials applied first came to be known as
initiators, and those applied subsequently
for a longer term were termed promoters.
In time, a more or less standardized assay
was developed to shorten the time required
to identify carcinogens and to discriminate
between initiators and promoters (10).
This assay, known as the initiation/promo-
tion (I/P) bioassay entails the application
of a known or suspected tumor initiator,
followed by multiple weekly treatments of
a known or suspected tumor promoter.
The I/P bioassay is designed to differ-
entiate substances that produce tumors by
genotoxic mechanisms, nongenotoxic
mechanisms, or both. Initiation is general-
ly agreed to occur when one or a few cells
ofa tissue have been exposed to a carcino-
gen at a level sufficient to cause a precan-
cerous, heritable, somatic, genetic event. A
number ofcharacteristics define the initiat-
ed cell, including a permanent change in
its DNA. Promotion is thought to involve
a number of changes in an initiated cell,
causing the initiated cell to grow faster
than the surrounding normal cells and to
develop into a visible neoplasm. Initiating
and promoting agents alone do not cause
neoplasms to appear, or only rarely so, but
in succession elicit both benign and malig-
nant neoplasms.
A number of researchers have investi-
gated the carcinogenicity ofvarious petro-
leum fractions (11-15). They have docu-
mented the initiating potential and car-
cinogenicity of streams containing PAHs
of characteristic structure and molecular
weight. They have also shown that some
fractions, which do not contain significant
concentrations of PAHs, are tumorigenic
in long-term assays and are promoters but
not initiators in the I/P bioassay.
The American Petroleum Institute
(API) assembled a task force of petroleum
company scientists and engineers to identi-
fy the various streams produced in petrole-
um refineries for which carcinogenicity
datawould be most useful. Thesewere test-
ed chronically, and a subset, reported in
this paper, was also tested using an I/P pro-
tocol to accomplish the following objec-
tives: 1) to investigate the carcinogenic
potential ofa number ofpetroleum streams
ofvarying volatility and composition; 2) to
identify the active streams as promoters or
initiators as defined by the I/P test proto-
col; 3) to investigate the correlation be-
tween results obtained in chronic studies
and in I/P studies to evaluate the I/P bioas-
say as a possible less expensive and shorter
alternative to the lifetime bioassay.
Methods
Chronic Study
The test articles listed in Table 1 were
obtained from the API repository (Exper-
imental Pathology Laboratories, Herndon,
Virgnia). These materials were among
those that had been selected by a task force
of the API to represent petroleum streams
produced during petroleum refining. These
streams have been characterized for inclu-
sion in the EPA listing ofmaterials covered
by Toxic Substances Control Act regula-
tions and given Chemical Abstract Service
(CAS) identification numbers. Table 1 is a
listing of the streams, their CAS numbers,
and boiling ranges. Toluene, ACS grade,
and benzo[a]pyrene (BaP) were purchased
from Aldrich Chemical Co. (Milwaukee,
Wisconsin).
Vacuum residuum was applied as a
50% (w/v) solution in toluene, and catalyt-
ic cracked clarified oil was applied as a 1%
(w/v) solution in toluene. All other test
articles were applied neat. We used BaP, a
well-known carcinogenic component of
crude petroleum, as the positive control.
BaP was applied as a 0.05% (w/v) solution
in toluene.
Male C3H/HeJ mice are most fre-
quently used in chronic dermal studies of
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Table 1. Petroleum streams samples examined
Petroleum stream CAS no. Boiling range, 0C
Solvent-refined heavy naphthenic distillate 64741-96-4 321-547
Hydrodesulfurized kerosene 64742-81-0 183-279
Sweetened naphtha 64741-87-3 37-128
Hydrodesulfurized middle distillate 64742-80-9 172-344
Vacuum residuum 64741-56-6 343
Catalytic cracked clarified oil 64741-62-4 350
Straight-run middle distillate / 64741-44-2/ 181-327
light catalytic cracked distillate 64741-59-9
Light catalytic cracked distillate 64741-59-9 240-372
Light paraffinic distillate 64741-50-0 304-428
petroleum-derived materials (11,13,14)
and therefore were used in this study. Mice
were acquired from Jackson Laboratories
(Bar Harbor, Maine). Mice were 7-9
weeks of age at study initiation. We ran-
domized mice upon receipt and double
housed them in suspended stainless-steel
cages for a quarantine period and then
housed them singly before study initiation.
Some groups were quarantined for 2 weeks
and held for 1 week, others were quaran-
tined for 1 week and held for 2. Purina
certified rodent chow #5002 was provided
ad libitum. Deionized tap water was pro-
vided ad libitum by bottle. Animal rooms
were maintained at 24.5 ± 1.7°C (SD) and
relative humidity at 40% ± 10% (SD). A
12-hr light/dark cycle was maintained.
We randomly divided 600 mice into
groups of50 mice each. Groups of50 mice
are routinely used in chronic skin painting
bioassays. In addition to the test groups,
one group received no treatment, and one
was administered BaP (0.05% w/v in
toluene) as the positive control. Because
two samples were diluted with toluene, a
separate toluene group was included as a
vehicle control. We applied the test arti-
cles, BaP, and toluene as 50-pl doses twice
weekly for a lifetime, or in the case ofthree
samples, 24 months. These three samples
showed significantly high tumor incidences
and short latencies to median tumor, so
the shorter exposure period did not affect
the classification of their carcinogenic
activity. All mice were sacrificed by ethyl
ether inhalation and exsanguinated by
puncturing the posterior vena cava.
We applied all materials to the shaved,
intrascapular region ofthe back. Mice were
clipped approximately every other week.
Materials were applied with a mechanical
pipet with disposable syringe and/or pipet
tip and allowed to spread evenly without
any intervention.
We performed physical examinations
for masses weekly. All mice were subjected
to a limited necropsy upon death or sacri-
fice. We removed application-site skin and
fixed it in 10% neutral buffered formalin.
Skin specimens were embedded in paraf-
fin, sectioned, stained with hematoxylin
and eosin, and examined microscopically.
Significance ofdifferences between test
and control tumor incidences was analyzed
by chi square (16). Fisher's exact test (one-
tailed) was used when comparing low
tumor-incidence groups (five or fewer mice
with tumors) to the appropriate control.
Final effective number (FEN) is the de-
nominator used in calculating tumor inci-
dence. When time to median tumor was
under 60 weeks, we used the number of
animals alive at that time as the FEN.
When time to median tumor was greater
than 60 weeks, the number ofanimals alive
at 60 weeks plus any mice dying with
tumors before 60 weeks was used as the
FEN. Latency was measured as the time in
weeks from initiation ofdosing to appear-
ance ofthe first tumor.
Initiation/Promotion Study
The test articles listed in Table 1 were
stored refrigerated in 25-ml glass bottles.
At 2-week intervals the test articles were
removed from the refrigerator for use.
Other reagents were purchased commer-
cially 7,12 dimethylbenzanthracene (DMBA)
from Eastman Kodak (Rochester, New
York), acetone, ACS grade, from EK
Industries (Addison, Illinois), phorbol-12-
myristate-13-acetate (PMA) from LC
Services Corporation (Woburn, Mass-
achusetts), and toluene, ACS grade, from
Fischer Scientific (Itasca, Illinois).
Vacuum residuum was applied as a
50% (w/v) solution in toluene, and the
catalytic cracked clarified oil was applied as
a 1% (w/v) solution in toluene. All other
test articles and toluene were applied neat.
DMBA, the usual initiator in promotion
investigations, was prepared one time only
in acetone at a concentration of 0.1%
(w/v). We prepared PMA in acetone every
2 weeks at a concentration of0.01% (w/v)
and stored it protected from light at
approximately 0°C.
Male CD-1 mice are routinely used as
test animals in I/P studies (12,15) and
were used in this investigation to permit
comparison with previous studies. Male
CD-I mice were acquired from Charles
River Breeding Laboratories (Portage,
Michigan). Mice were 4-5 weeks old upon
receipt and 7-9 weeks old at study initia-
tion. They were determined to be free of
viral antibodies upon arrival and were
quarantined for at least 2 weeks before
study initiation. Animals were housed
singly at the time of randomization for
study initiation and remained housed
singly throughout the study in suspended
stainless-wire cages. Rodent chow 5001
(Ralston Purina Co., St. Louis, Missouri)
and tap water were provided adlibitum by
means of an automatic watering system.
The animal room temperatures were main-
tained at 21.3YC ± 1.6 (SD), and relative
humidity at 54.5% ± 13.3 (SD). Animal
rooms were illuminated with fluorescent
lights and maintained on a 12-hr light/
dark cycle.
In the initiation phase, we randomly
divided 360 mice into 12 groups of 30
each. This number of mice per group has
been shown to provide satisfactory sensitiv-
ity and selectivity in I/P studies (12,15). In
addition to the nine test articles, acetone
was used as a negative control, and DMBA
was the positive control. Because two sam-
ples were diluted in toluene, a separate
toluene-initiated group was included as a
vehicle control. The test articles, acetone,
and toluene were applied as five consecu-
tive daily applications of50 pl. In the posi-
tive control group, 50 pl ofDMBA (0.1%
w/v in acetone) was applied once on the
last day ofthe dosing week. After a 2-week
rest period, 50 pl of PMA promoter
(0.01% w/v in acetone) was applied to
each animal twice weekly for 25 weeks.
Physical examinations including observa-
tions of dermal masses were performed
weekly on all surviving mice until study
completion. We sacrificed all mice by
intraperitioneal injection of nembutal the
week of PMA treatment termination, sub-
jected mice to gross necropsy, and took
skin sections for histopathological exami-
nation.
In the promotion phase, we randomly
divided 630 mice into 21 groups of 30
mice each. Test article groups were the
same as for initiation except that neither
acetone nor PMA was tested as promoters.
A negative control was added (sham-han-
dled), which received no treatments after
initiation. All mice were initiated with 50
pl of DMBA (0.1% w/v in acetone). In
addition, each mouse in an identical series
of test article groups of 30 mice each,
except the sham-handled group, was treat-
ed with a single 50-pl dose ofacetone as a
negative initiating agent. After a 2-week
rest period, the mice in each DMBA or
acetone-initiated group received 50 pl of
the test articles or toluene twice a week for
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all mice by injection of intraperitoneal
nembutal, subjected mice to gross necrop-
sy, and took skin sections for histopatho-
logical examination. The procedures for
skin preparation, dosing, and examinations
were the same as those followed in the
chronic study.
The outcome measures were 1) time to
appearance of first tumor, 2) number of
animals with clinically observed tumors,
and 3) number of animals with histologi-
cally confirmed tumors. Statistical signifi-
cance of treatment effect in the initiation
study was assessed by comparison with the
acetone-initiated group. In the promotion
study, each sample had its own DMBA-
and acetone-initiated groups and compar-
isons were made between them. We used
two different statistical methods in the
analysis ofthese data. For the time to first
tumor data, a product-limit survival analy-
sis (17) was used to contrast the survival
distributions for the desired pairwise group
comparisons. To analyze the number of
animals with tumors, a one-tailed Fisher's
exact test (18) was performed to determine
whether the incidence of histologically
confirmed tumors in the sample group was
higher than its respective control. The type
I error rate used for all statistical compar-
isons was 5%.
Results
Irritation and inflammation at the dosing
site were common in the exposed groups,
with the most severe signs noted in mice
exposed to light catalytic, cracked distillate,
hydrodesulfurized middle distillate, and
the mixture of 50% straight run, middle
distillate/50% light catalytic, cracked dis-
tillate. A number ofskin tumor types were
noted: benign neoplasms classified as fibro-
mas, papillomas, keratoacanthomas, and
hemangiomas, and malignant neoplasms
including squamous cell carcinomas,
fibrosarcomas, and malignant melanomas.
The incidence of keratoacanthomas, hem-
angiomas, and malignant melanomas was
extremely low. Only one mouse in each of
two different groups developed heman-
giomas and only one a keratoacanthoma.
Two mice in one group had malignant
melanomas. At the time ofmicropatholog-
ical examination, most ofthe tumors were
malignant. This is not inconsistent with
expectations based on a two-stage model of
carcinogenesis suggesting that initiated
(first stage) cells have an increasing proba-
bility ofundergoing a second stage (malig-
nant) change as the mouse ages. The
results are given in Table 2.
The samples in this study represent
complex mixtures derived from distillation
of petroleum and different refining treat-
ments. The most volatile, sweetened naph-
Table 2. Tumor status of mice after chronic dermal exposure
No. of mice Latency Malignanttumor Total tumor
Treatment groups with tumors (weeks) incidence (%) incidence (%)
Sham-handleda 0 O 0
Hydrodesulfurized kerosenea 24 76 59* 57
Sweetened naphthaa 3 113 7 2
Hydrodesulfurized middle distillatea 27 72 63 58
Vacuum residuum, 50%a 5 113 10+ 6
Catalytic cracked clarified oil, 1%a b 45 72 100 100
Solvent-refined heavy naphthenic distillate 3 ND 6 ND
Straight run middle distillate, 16 70 39 34
light catalytic cracked distillate, 50/50
Light catalytic cracked distillateb 39 40 87: 80
Light paraffinic distillateb 36 67 78 69
Toluenea 4 111 9 9
Tolueneb 0 0 0
BaP, 0.05%a 49 49 100 100
BaP, 0.05%b 46 47 98 94
Abbreviations: ND, not determined; BaP, benzo[a]pyrene.
aLifetime exposure.
b104weeks of exposure.
Chi-square test, differentfrom sham-handled (p <0.05).
Fisher's exacttest, one-tailed, not higherthan sham-handled (p<0.05).
+Fisher's exacttest, one-tailed, not higherthan toluene control (p < 0.05).
tha, does not demonstrate significant
tumorigenic potential. This is also true for
vacuum residuum, a nonvolatile fraction
containing high molecular weight com-
pounds including PAHs. Since this stream
was diluted 50% in toluene, statistical
comparison was made with the toluene sol-
vent control rather than acetone.
BaP, a strong dermal carcinogen, pro-
duced tumors in virtually all exposed ani-
mals in this study at a concentration of
0.05%. The only petroleum stream that
approached it in activity was catalytic,
cracked clarified oil, which achieved 100%
incidence at a concentration of 1%. Sol-
vent-refined heavy naphthenic distillate
lacked carcinogenic activity in the chronic
study.
Except for light paraffinic distillate, the
rest of the samples can be characterized as
middle distillates with boiling ranges in the
region of 150°-370°C. These streams
appear to be tumorigenic after chronic der-
mal application under the conditions of
this experiment. The skins ofmice chroni-
cally exposed to the middle distillate sam-
ples evidenced severe irritation with in-
flammation, some erosion, and scab forma-
tion.
The tumors seen in the I/P study were
overwhelmingly benign squamous cell
papillomas and keratoacanthomas. The
only malignant tumors, squamous cell car-
cinomas, occurred in two mice of the
group promoted with light catalytic
cracked distillate. Table 3 details the tumor
incidence and latency after initiation and
promotion phases ofthis assay.
The only samples manifesting initiating
activity, as shown in Table 3, were 1% cat-
alytic cracked clarified oil and light paraf-
finic distillate. The catalytic cracked clari-
fied oil was almost as potent as 0.1%
DMBA. catalytic cracked clarified oil does
not appear to have promoting potential,
although this lack of activity may be a
result of the low concentration tested
(1%). Light paraffinic distillate appears to
have promoting as well as initiating poten-
cy.
The middle distillate samples (hydro-
desulfurized kerosene, hydrodesulfurized
middle distillate, light catalytic cracked dis-
tillate, and the 50/50 mixture of straight
run middle distillate/light catalytic cracked
distillate) acted as pure promoters in the
I/P assay with no significant initiating
potential. Lastly, a heterogeneous trio of
samples, sweetened naphtha, vacuum
residuum, and solvent-refined heavy naph-
thenic distillate, failed to demonstrate ini-
tiating or promoting activity.
In the initiating phase, there was some
inverse correlation between tumor inci-
dence and latency with exceptions such as
vacuum residuum, which had a low inci-
dence and low latency. This did not appear
to be the case in the promoting phase,
however, where the latencies were quite
similar for all tested groups developing
tumors.
As noted previously, the only tumors
occurring in chronic and I/P studies at
higher than incidental rates were squamous
cell carcinomas, squamous cell papillomas,
fibrosarcomas, and keratoacanthomas.
Table 4 lists the incidence rates of these
tumors in both studies. The bulk of the
neoplasms in the chronic study were squa-
mous cell carcinomas with a significant
representation of the fibrosarcomas and a
relatively small incidence of squamous cell
papillomas. As noted previously, all the
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Table 3. Initiating and promoting potential of petroleum streams
Initiating phase Promoting phase
Treatment groups Incidencea Latency(weeks) Incidence' Latency(weeks)
Sham-handled NT NT 0
Hydrodesulfurized kerosene 3/30 25 22/30* 14**
Sweetened naphtha 3/29 20 0
Hydrodesulfurized middle distillate 6/30 18 16/30* 13**
Vacuum residuum 7/30 10 0
Catalytic cracked clarified oil, 1% w/v 26/30* 9** 5/29 8**
Solvent-refined heavy naphthenic distillate 4/30 22 0
Straightrun middle distillate/ 5/29 13 18/30* 13**
light catalytic cracked distillate 50/50
Light catalytic cracked distillate 9/30 15 28/30*(2)b 11**
Light paraffinic distillate 14/30* 12** 8/29* 12**
Toluene 8/29 13** 2/30 26
Acetone 3/30 16 NT NT
DMBA,0.1%w/v 30*/30(1)b 9** NT NT
Abbreviations: NT, nottested; DMBA, 7,12-dimethylbenzanthracene.
aIncidence = number of mice with tumors/number surviving 20 weeks of exposure.
bNumber of malignant tumors in parentheses.
*Significanrtly higher than its acetone control (p <0.05) using one-tailed Fisher's exact test.
**Significantly different from acetone control (p<0.05) using Kaplan-Meier test.
study were benign squamous cell papillo- over, analysis of the stream revealed no
mas and keratoacanthomas, with the known carcinogenic components. The lack
exception of two mice with squamous cell of activity may be due to one or both of
carcinomas in the groups exposed to light these factors. Vacuum residuum is the least
catalytic cracked distillate. Aside from the volatile of the streams and does not begin
fibrosarcomas, these are tumors of epider- to distill below 350'C. No analytical data
mal origin that might be expected to arise were available on this stream, but it is
from dermal treatment with a tumorigen. expected to contain some high molecular
weight PAHs. These compounds may not
Discussion be carcinogenic, explaining the innocuous
Three streams in this study did not show character of the stream. Alternatively, any
statistically significant carcinogenic activity active materials in vacuum residuum, if
chronically or in I/P tests: sweetened naph- they exist, may not be available to the skin
tha, solvent-refined heavy naphthenic dis- cells at risk for carcinogenic transforma-
tillate, and vacuum residuum. Sweetened tion. Lewis (14) has reported similar results
naphtha, a volatile fraction boiling in the from the nonvolatile asphalt fraction of
range of 370-128"C, was made up mostly crude oil. Solvent-refined heavy naph-
of paraffinic hydrocarbons, some naph- thenic distillate is a mineral oil that has
thenes, and a low concentration ofaromat- been extracted to remove any carcinogenic
ics. The low boiling range of this stream PAHs. Kane et al. (13), Doak et al. (19),
implies that it will have a short residence and Halder et al. (20) have reported that
time on the skin after application. More- intensive solvent refining is effective in
Table 4. Incidence (%) of tumor types in chronic and initiation/promotion (I/P) studies
I/P study
Chronic study SCP KA
Stream (exposure time)a SCC SCP FS P P
Hydrodesulfurized kerosene (L) 36 2 10 10 63 0 20
Sweetened naphtha (L) 2 4 0 10 0 0 0
Hydrodesulfurized 46 2 12 20 53 0 7
middle distillate (L)
Vacuum residuum (L) 6 0 2 20 4 3 0
Catalytic cracked clarified oil, 1%(L) 74 8 14 83 17 23 0
Solvent refined heavy naphthenic distillate(L) 8 0 0 13 0 0 0
Straight-run middle distillate/light catalytic 22 8 6 14 60 7 10
cracked distillate, 50/50(L)
Light, catalytic cracked distillate (24) 54 14 24 27 90 10 33
Lightparaffinic distillate(24) 54 12 16 40 28 17 0
Toluene (24) 0 0 0 24 7 3 0
Toluene (L) 6 0 2
BaP (24) 32 4 62 83 NT 50 NT
BaP(L) 68 0 44
Abbreviations: SCC, squamous cell carcinoma; SCP, squamous cell papilloma; FS, fibrosarcoma; KA, ker-
atoacanthoma; BaP, benzo[alpyrene.
aL, lifetime; 24, 24 months.
eliminating the carcinogenic potency of
mineral oils. [ARC has affirmed that judg-
ment with the statement, "There is no evi-
dence that severely solvent-refined oils are
carcinogenic to experimental animals" (21:
151).
Two streams, catalytic cracked clarified
oil and light paraffinic distillate, exhibited
carcinogenic activity in the chronic study
and were classified as initiators in the I/P
study. Catalytic cracked clarified oil is a
residual fraction from distillation of the
products of a catalytic cracking process. It
is likely to contain active PAHs, some of
which may be heterocyclic. The lack of
activity of this stream as a promoter may
be a result of its dilution (1%) rather than
any intrinsic property of the stream itself.
Light paraffinic distillate is a mineral oil of
relatively low viscosity with a high enough
boiling range that it may contain low con-
centrations of PAHs, which may be re-
sponsible for its activity. The initiating
activity ofthis stream is weak compared to
that of the DMBA-positive control and
catalytic clarified oil, reflecting the weak
carcinogenicity relative to these materials
in the chronic study.
The middle distillate samples (hydro-
desulfurized kerosene, hydrodesulfurized
middle distillate, light catalytic cracked dis-
tillate, and the 50/50 mixture of straight
run middle distillate and light catalytic
cracked distillate) were all consistent in
their activities. They all led to tumor for-
mation on chronic application, with a
rather narrow range ofincidence rates, and
they proved to be promoters but not initia-
tors in the I/P bioassay. Other studies have
documented similar activity in middle dis-
tillate fractions and streams (11,12,14,22).
The concentrations ofactive PAHs in these
streams are normally too low to be respon-
sible for middle distillate tumorigenic
potency (11), and some studies (12,23)
have reported that they act as promoters
but not initiators as defined in a standard
I/P bioassay.
Of the tumor types listed in Table 4,
the squamous cell papillomas and carcino-
mas and the keratoacanthomas are epider-
mal in origin, whereas the fibrosarcomas
derive from mesodermal tissue. The squa-
mous cell carcinomas found in the chronic
study might reasonably be regarded as suc-
cessors to the papillomas and keratoacan-
thomas noted in the shorter-term I/P
study, representing the malignant stage
after early benign epidermal tumors. The
fibrosarcomas, however, cannot be so
regarded, and their appearance in the
chronic study is difficult to interpret. The
mouse strains in the study were different,
C3H in the chronic study and CD-1 in the
I/P study, and the fibrosarcomas may rep-
resent apeculiar reaction ofthe C3H strain
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after dermal exposure to carcinogens.
However, Biles et al. (11) used C3H mice
in their study of chronic dermal applica-
tion of middle distillate samples and iden-
tified only one fibrosarcoma in 490 mice
in the 10 groups tested. It appears that the
C3H strain is not consistently susceptible
to the development of fibrosarcomas. In
any event, the appearance offibrosarcomas
in the chronic study does not affect the
good correlation of the I/P study with the
chronic investigation as far as tumorigenic
activity is concerned.
Table 5 summarizes the activity of the
various petroleum streams tested in this
investigation in both chronic and I/P stud-
ies. The results of the chronic bioassay in
this investigation are consistent with previ-
ous studies (11,13,14), which have shown
the following: 1) the most volatile streams
are inactive, 2) the least volatile residues
(vacuum residuum) are also inactive, 3)
untreated distillates (light paraffinic distil-
late in this study) are active but may be
made inactive by suitable treatment to
remove PAHs (solvent-refined heavy naph-
thenic distillate in this study), 4) middle
distillates show carcinogenic activity in
chronic dermal studies.
The I/P investigations carried out in
this study demonstrate convincingly that
the middle distillates with carcinogenic
activity in the chronic study act as promot-
ers and not as initiators. This too supports
results of previous investigations (12,15).
The activity of the two streams showing
initiation potential, 1% catalytic cracked
clarified oil, and light paraffinic distillate,
may result from the presence of active
PAHs and/or polyaromatic heterocycles in
the case ofcatalytic cracked clarified oil.
The I/P portion of the investigation
demonstrated perfect correlation with the
chronic phase in that all streams negative
in the chronic bioassay were inactive as ini-
tiators and promoters, and all streams posi-
tive in the chronic bioassay were active in
either the initiation phase or promotion
phase or both. This indicates, at least for
petroleum streams, that the I/P bioassay
may be a cost-effective substitute for the
chronic test. Results would be available in
6 months rather than 2 years, providing
earlier information at a lower cost. It would
also furnish additional information with
regard to the nature of the carcinogenic
activity, which might be useful in assessing
hazard.
The significance of the distinction
between initiation and promotion in regard
to risk assessment of petroleum streams
remains to be clarified, and an API consor-
tium is currently sponsoring research in the
field. Over a number ofyears, hypotheses
have been put forth regarding the develop-
ment ofat least some cancers as a two-stage
process (24-27). These authors and their
co-workers have demonstrated that the
time course oftumor incidence can be suc-
cessfully modeled using this approach for
naturally occurring tumors in humans (27)
or for chemically induced cancers in experi-
mental animals (24,28). One element of
great significance in the model is cellular
proliferation, with critical importance asso-
ciated with the particular cell stage affected
and the schedule of proliferation. If initia-
tion in the I/P bioassay is considered to
correspond to initiation in the two-stage
model and promotion to providing a prolif-
erative advantage to the initiated cells, skin
carcinogenic activity by promoters can be
examined using this model.
McKee et al. (15) have documented that
skin irritation and hyperplasia are caused by
repeated application ofmiddle distillates to
mouse skin, and Skisak (23) has shown that
elimination of these effects can reduce or
eliminate tumor development after middle
distillate exposure. If compensatory hyper-
plasia provides a proliferative advantage to
initiated cells, the dermal carcinogenic activ-
ity ofmiddle distillates can be visualized as
promotion of cells initiated by exposure to
background environmental mutagens. One
consequence ofapplication ofthe two-stage
model is that the results ofa chronic bioas-
say of a promoter cannot be applied un-
critically to risk assessment (25). Because
cellularproliferation is afunction ofthe der-
mal application schedule, which is different
in the experimental situation than in human
experience, direct extrapolation will proba-
blylead to erroneous conclusions.
Table 5. Comparative chronic and initiation/promotion activity of petroleum streams
Carcinogenic activity
Stream Chronic Initiation Promotion
Hydrodesulfurized kerosene + - +
Sweetened naphtha - - -
Hydrodesulfurized middle distillate + - +
Vacuum residuum
Catalytic cracked clarified oil, 1% + +
Solvent-refined heavy naphthenic distillate
Straight run middle distillate/
light catalytic cracked distillate, 50/50 + - +
Light catalytic cracked distillate + - +
Lightparaffinic distillate + + +
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